Article

Lucentis approved for diabetic retinopathy treatment by FDA

The FDA has approved Genentech’s ranibizumab injection (Lucentis) for the treatment of diabetic retinopathy in patients with diabetic macular edema (DME).

South San Francisco, CA-The FDA has approved Genentech’s ranibizumab injection (Lucentis) for the treatment of diabetic retinopathy in patients with diabetic macular edema (DME).

The FDA granted ranibizumab Breakthrough Therapy Designation and Priority Review for the indication based on results from the RISE and RIDE phase III clinical trials.

“While there are various options for treating DME, before today none were approved showing improvement in retinopathy,” said Sandra Horning, MD, chief medical officer and head of global product development for Genentech. “With today's approval, people with DME now have an FDA-approved medicine that showed meaningful improvements in retinal damage from diabetes, in addition to the established improvement in vision.” 

According to the company, ranibizumab was the first medicine approved by the FDA for the treatment of DME in 2012, and has been an important option for patients with wet age-related macular degeneration since 2006 and macular edema following retinal vein occlusion since 2010.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game (Part 2)
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game? (Part 1)
(Image credit: Ophthalmology Times) From MIGS to gene therapy: Inder Paul Singh, MD, celebrates the past and future of glaucoma care
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
© 2025 MJH Life Sciences

All rights reserved.